Full-Time

Senior Manager, SAP GMX Data & Analytics Solutions

Posted on 8/18/2026

Deadline 8/26/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$111.9k - $207.4k/yr

+ 17.5% bonus target + Share-based long-term incentive program

No H1B Sponsorship

Collegeville, PA, USA + 3 more

More locations: Lake Forest, IL, USA | Tampa, FL, USA | New York, NY, USA

Hybrid

Hybrid schedule requires 2–3 days on-site per week. Occasional domestic or international travel may be required.

Bachelor's

Category
Engineering Management (1)
Required Skills
Software Testing
GMP
SAP Products
Data Modeling
Data Analysis

Get referred to Pfizer

See people who can refer or advise you

Requirements
  • A bachelor’s degree in Information Systems, Computer Science, Finance, Engineering, Business, or a related field.
  • At least 10 years of experience in SAP BW, SAP BPC, Finance data solutions, enterprise reporting, or data platform delivery with hands-on leadership.
  • Experience with data ingestion using DataSources, ODQ, InfoPackages, DTPs, process chains, and delta load management.
  • Experience with data modeling using Advanced DSOs, Composite Providers, Open ODS Views, Analytic Indexes, and ABAP transformation routines.
  • Experience developing BW queries using BEx Query Designer or BW Modeling Tools, calculated and restricted key figures, variables, exceptions, and conditions.
  • Experience building and maintaining Analysis for Office workbooks and input-ready planning templates.
  • Experience with BPC planning functions, FOX formula scripts, data manager packages, planning sequences, and input schedules.
  • In-depth ABAP programming knowledge.
  • Experience troubleshooting extraction, transformation, loading, query performance, and BPC planning inconsistencies end to end.
  • Deep experience with GMX, EarnIn, Finance close, certifications, reconciliations, or related financial reporting processes.
  • Experience with SAP BPC Standard or Embedded, including planning model configuration, logic scripts or FOX formulas, input schedules, and consolidation processes.
  • Experience leading teams, managing direct reports, or providing formal work direction to matrixed or contracted resources.
  • Functional knowledge of SAP S/4HANA Sales and Distribution, including pricing condition technique, condition types, condition tables, access sequences, pricing procedures, and condition records.
  • Working knowledge of SAP Material Master data concepts and their relevance to BW extraction and reporting.
  • Finance domain knowledge in Product Costing, including standard cost estimates, cost component structures, material ledger or actual costing, and variance analysis.
  • Finance domain knowledge in General Ledger, including G/L account master data, document types, posting keys, and period-end closing processes.
  • Understanding of Finance master data governance, including company codes, controlling areas, cost centers, profit centers, and G/L account master data structures.
  • Experience with SOX, GMP, audit, compliance, validation, or financial control expectations.
  • Ability to work in a fast-paced, dynamic environment while managing competing priorities.
Responsibilities
  • Lead, mentor, and provide direction to matrix colleagues, analysts, managers, contractors, and vendor resources supporting GMX data and analytics work.
  • Set priorities, manage capacity, review deliverables, and ensure high-quality execution across internal and external resources.
  • Manage vendor execution, deliverable quality, responsiveness, documentation, and adherence to Pfizer standards.
  • Support sourcing, onboarding, knowledge transfer, succession planning, and continuity for critical GMX analytics capabilities.
  • Own the global GMX data, analytics, and reporting solution portfolio across SAP BW, SAP BPC, SAP S/4HANA integrations, and related reporting platforms.
  • Serve as a senior Digital point of accountability for GMX-enabled analytics, reporting, reconciliation, and certification capabilities.
  • Provide strategic direction for GMX solution design, data architecture, reporting enablement, operational stability, and modernization.
  • Ensure GMX solutions support critical Finance, Controllers, Supply Chain, and enterprise reporting needs.
  • Drive roadmap planning for GMX data and analytics capabilities while balancing transformation, regulatory expectations, business demand, and operational continuity.
  • Provide senior judgment on complex GMX data issues, financial reporting dependencies, SAP integration risks, and cross-functional process impacts.
  • Manage the GMX demand pipeline with business stakeholders, Digital leads, and portfolio governance teams.
  • Evaluate incoming work based on business value, urgency, regulatory or compliance impact, technical feasibility, and resource capacity.
  • Define delivery roadmaps balancing transformation initiatives, business enhancements, regulatory needs, and business-as-usual stability.
  • Act as a senior GMX solution subject matter leader for Finance, Controllers, Digital, SAP platform teams, and business stakeholders.
  • Lead cross-functional governance discussions, design reviews, roadmap planning sessions, escalation forums, and executive-ready updates.
  • Translate complex SAP, Finance, GMX, and data architecture topics into business-oriented recommendations and decisions.
  • Influence senior stakeholders to align priorities, solution direction, risk mitigation, and adoption strategies.
  • Communicate status, risks, decisions, dependencies, and outcomes at senior leadership levels.
  • Build partnerships across business, Digital, compliance, and vendor teams to drive sustainable business value.
  • Lead end-to-end delivery across requirements, design, development, testing, deployment, stabilization, and support transition.
  • Provide senior oversight for multiple initiatives, ensuring delivery quality, consistency, documentation, and production readiness.
  • Drive root-cause analysis and long-term remediation for recurring production issues, data defects, reconciliation breaks, and process inefficiencies.
  • Ensure development work follows approved standards, naming conventions, code review practices, testing expectations, and release governance.
  • Improve operational processes through automation, monitoring, standardization, knowledge management, and continuous improvement.
  • Ensure business-critical GMX processes have appropriate support coverage, escalation paths, and continuity planning.
  • Establish and maintain governance standards for GMX data, analytics, reporting, certifications, reconciliations, and documentation.
  • Ensure solutions adhere to SDLC, change control, testing, validation, audit, compliance, and data governance requirements.
  • Maintain audit-ready artifacts, process documentation, design decisions, control evidence, and operational playbooks.
  • Partner with compliance, audit, quality, Finance, and technical teams to address control gaps and improve traceability.
  • Ensure testing strategies include unit, integration, regression, reconciliation validation, business acceptance, and production readiness testing.
  • Provide senior-level risk assessment and mitigation planning for production issues, compliance concerns, data integrity risks, and business-impacting defects.
  • Provide status updates to leadership on delivery progress, risks, issues, decisions, and business impact.
  • Prepare materials for governance forums, steering discussions, stakeholder reviews, and operational checkpoints.
  • Escalate critical risks and system issues in a timely and structured manner, including recommended mitigation options.
  • Drive adoption through demonstrations, knowledge-sharing sessions, training support, and stakeholder engagement.
Desired Qualifications
  • SAP certification in BW, BPC, or SAP Analytics Cloud.
  • Experience with SAP Analytics Cloud or SAP BOBJ tools.
  • Ability to develop roadmaps, manage portfolio demand, and communicate delivery outcomes to senior stakeholders.
  • Experience in a pharmaceutical, life sciences, or regulated industry.
  • Breadth of diverse leadership experiences and capabilities, including influencing and collaborating with peers, developing and coaching others, and overseeing and guiding colleagues’ work to achieve outcomes and business impact.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Pfizer raised 2026 revenue guidance to $60.5-$62.5 billion on August 4, 2026.
  • Ex-COVID revenue grew 5% in Q2 2026, driven by Eliquis and Padcev.
  • FDA priority review for Talzenna-Xtandi targets a Q4 2026 approval decision.

What critics are saying

  • Eliquis loses U.S. exclusivity in 2028, threatening Pfizer’s biggest 2026 revenue engine.
  • Paxlovid fell 95% and Comirnaty dropped 34% in Pfizer’s second quarter 2026.
  • If Eliquis replacement and pipeline launches fail, Pfizer becomes a slow-decline cash distributor.

What makes Pfizer unique

  • Pfizer pairs Eliquis scale with oncology assets like Padcev and Talzenna in 2026.
  • Prevnar 20 won Québec public funding in May 2026, deepening vaccine franchise access.
  • Pfizer and Valneva’s Lyme vaccine moved into EMA review on August 14, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-4%
Yahoo Finance
Aug 19th, 2026
Intel CEO invests $10M in shares as chipmaker posts 25% revenue growth driven by AI demand

Intel CEO Lip-Bu Tan purchased nearly $10 million worth of shares as part of the chipmaker's recent stock offering, signalling confidence in the company's turnaround. Intel recently reported revenues of $16.1 billion, growing 25% year-over-year, with its Data Centre and AI business unit seeing revenue surge nearly 60% to $6.3 billion. CoStar Group founder and CEO Andrew Florance purchased 83,300 shares totalling roughly $2.5 million. Pfizer CEO Albert Bourla similarly invested, purchasing 38,000 shares for just over $1 million. These insider purchases reflect executives' confidence in their companies' longer-term outlook, with investors often viewing such moves as a positive signal.

Yahoo Finance
Aug 18th, 2026
Two profitable stocks with solid fundamentals and one to ignore

Two companies leverage profitability to outpace competitors, whilst another faces headwinds, according to StockStory's analysis. Primoris, which builds and maintains infrastructure in utility, energy, and civil construction sectors, struggles with a low gross margin of 10.3% reflecting high production costs. The company has seen falling earnings per share over two years and weak free cash flow margin of 2.2% over five years. BrightSpring Health Services, offering home health care and pharmacy services, has posted 23.9% annual revenue growth over two years. Its revenue base of $14.37 billion provides economies of scale. Pfizer's massive $63.7 billion revenue base gives it significant negotiating power. The pharmaceutical giant's adjusted operating margin expanded by 18.5 percentage points over two years, whilst delivering a 17.5% return on capital.

Yahoo Finance
Aug 11th, 2026
Pfizer raises 2026 guidance to $62.5B, but boost relies on Eliquis facing patent expiry

Pfizer reported second-quarter revenue of $15 billion, up 3% year over year, and raised its 2026 revenue guidance to between $60.5 billion and $62.5 billion. However, investors showed limited enthusiasm. The pharmaceutical giant's anticoagulant Eliquis, shared with Bristol Myers Squibb, generated $2.4 billion in quarterly revenue, up 21% year over year. The drug is now Pfizer's best-selling product. The concern is that Eliquis will lose patent exclusivity by the end of the decade. Pfizer's increased reliance on a drug facing imminent generic competition may signal it has yet to identify a suitable replacement. The company is expanding its pipeline, particularly in the GLP-1 market, where its candidate berobenatide is undergoing phase 3 trials after posting strong phase 2 results.

Yahoo Finance
Aug 11th, 2026
Pfizer raises guidance to $62.5B as BioNTech cuts forecast amid $928M loss

Pfizer and BioNTech reported contrasting second-quarter 2026 results as their post-pandemic strategies diverge. While the European Commission authorised their updated COVID-19 vaccine on 29 July, the former partners now face different financial realities. Pfizer posted revenues of $15 billion, up 1% operationally year-over-year. Excluding COVID products, revenue grew 5%, driven by strong performance from Eliquis, Padcev, and other non-COVID products. The company raised full-year revenue guidance by $500 million to $60.5–$62.5 billion and announced productivity initiatives expected to deliver $2.5 billion in additional savings between 2027 and 2029. BioNTech revenues fell 59.5% to €105.6 million as COVID vaccine demand declined. The company reported a net loss of €820.8 million and reduced full-year revenue guidance to €1.6–€1.9 billion. BioNTech maintains €16.6 billion in cash reserves.

Yahoo Finance
Aug 10th, 2026
Pfizer's earnings fall 58%, but dividend appears safe for now

Pfizer reported a 58% decline in net income for the first half of 2024, falling to $2.4 billion from $5.9 billion year-over-year. The decline was largely driven by $3.8 billion in non-cash impairment charges related to in-process research and development assets. Despite the earnings drop, the dividend appears sustainable. Over the past four quarters, Pfizer generated $11 billion in free cash flow, exceeding the approximately $9.8 billion paid in dividends. The company has struggled with growth whilst managing restructuring costs and integrating recent acquisitions. Its second quarter ended 30 June with a $248 million net loss. Pfizer's stock has fallen 44% over five years, though it's up 9% year-to-date. The dividend currently yields 6.4%.